🇺🇸 FDA
Pipeline program

Privigen 100 mg/ml solution for infusion, Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

80202135CDP3001

Phase 2 small_molecule active

Quick answer

Privigen 100 mg/ml solution for infusion, Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135 for Chronic Inflammatory Demyelinating Polyneuropathy is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Chronic Inflammatory Demyelinating Polyneuropathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials